HIPAA Compliant
ISO 27001 CertifiedActively Recruiting
Led by University of Alberta · Updated on 2026-07-09
100
Participants Needed
10
Research Sites
26 weeks
Total Duration
This trial evaluates the effects of different dose-intensities of continuous renal replacement therapy CRRT in critically ill patients with acute kidney injury AKI in the intensive care unit. The main goal is to compare the current standard CRRT dose-intensity with a lower dose to see if the lower dose is not worse and might improve kidney recovery and shorten the duration of CRRT. The study addresses the lack of clear evidence on the minimum effective CRRT dose and aims to generate high-quality data that could influence clinical guidelines and practice. Participants will be randomly assigned to receive either a low dose-intensity CRRT of 10-15 mLkghour or the standard dose-intensity of 25-30 mLkghour while on CRRT. The lower dose is based on observational data suggesting it may be safe and well tolerated. The trial is a pilot feasibility study designed to inform a larger randomized controlled trial. Treatments will be delivered continuously while patients are in the ICU needing CRRT. During the study, participants will be monitored for the delivered CRRT dose-intensity over about one month. Researchers will assess feasibility factors such as consent rate, adherence to dose, recruitment rate, and outcome ascertainment up to 90 days. The primary outcome focuses on the difference in CRRT dose delivered. Participants will receive regular evaluations to track kidney recovery, time on CRRT, and overall treatment effects. The trial runs from November 2024 to June 2027.
CONDITIONS
LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM)
S
Sean M Bagshaw, MD
E
Ellen Morrison, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Alberta
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Low Dose-Intensity CRRT | Standard Dose-Intensity CRRT |
|---|---|---|
| What it is | CRRT delivered at a lower continuous dose-intensity to critically ill adults with acute kidney injury in the ICU. | CRRT provided at standard (higher) continuous dose-intensity commonly used for critically ill adults with acute kidney injury. |
| Role in the trial | Participants were randomized to receive CRRT at a lower dose-intensity as the experimental intervention. | Serves as the active comparator arm, with participants given standard dose-intensity CRRT. |
| Primary use | Investigational use to determine whether a lower CRRT dose-intensity is feasible and effective for AKI management in ICU patients. | Reflects current practice of using a standard dose-intensity CRRT as recommended in many clinical protocols for AKI in critically ill individuals. |
| How it is given or performed | Participants receive lower intensity CRRT continuously via extracorporeal circuit in the ICU, initiated within 24 hours of starting CRRT. | Participants receive standard intensity CRRT continuously in the ICU, following established dosing protocols. |
| Evidence status | Ongoing investigation; outcome results from this trial are not yet available. | Standard dose-intensity CRRT has published evidence supporting its use for critically ill AKI patients; clinical guidelines recommend its application with close attention to individual patient needs. |
| Important limitations | Actual risks or benefits of lower intensity CRRT are unknown; study is needed to confirm feasibility and effectiveness compared to current practice. | Standard intensity CRRT may increase resource use and drug clearance compared to lower doses; optimal dosing is debated and should be tailored to individual patients. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - About 1 month
Participants receive continuous renal replacement therapy at either a low dose-intensity or standard dose-intensity while in the intensive care unit.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
William Beaubien-Souligny, Melissa Thompson Bastin, J Pedro Teixeira...
https://pubmed.ncbi.nlm.nih.gov/40779331/University of Alberta
Lead Sponsor
